Management of acute coronary syndromes with fondaparinux
Harm Wienbergen, Uwe ZeymerHerzzentrum Ludwigshafen, Medizinische Klinik B, GermanyAbstract: Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially avaliable for clinical use. It has been approved for the prevention of venous thromboembolism in patients unde...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2007-07-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | https://www.dovepress.com/management-of-acute-coronary-syndromes-with-fondaparinux-peer-reviewed-article-VHRM |